{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.69"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"cGVHD definition is based on BMT CTN MOP SEPT. 2005; outlined in Protocol Appendix III.","groups":[{"description":"Conventional bone marrow transplant (BM)","id":"OG000","title":"Control BM Arm"},{"description":"G-CSF (filgrastim) stimulated bone marrow (G-BM)","id":"OG001","title":"Experimental G-BM Arm"}],"paramType":"NUMBER","populationDescription":"Included only patients survived beyond 100 days.","reportingStatus":"POSTED","timeFrame":"18 months post-transplant","title":"Estimated Percentage of Chronic Graft-versus-host Disease (cGVHD)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}